DK2573176T3 - Tumorvæksthæmmende forbindelser og fremgangsmåder til anvendelse deraf - Google Patents

Tumorvæksthæmmende forbindelser og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2573176T3
DK2573176T3 DK12198310.0T DK12198310T DK2573176T3 DK 2573176 T3 DK2573176 T3 DK 2573176T3 DK 12198310 T DK12198310 T DK 12198310T DK 2573176 T3 DK2573176 T3 DK 2573176T3
Authority
DK
Denmark
Prior art keywords
cells
oligonucleotide
treatment
cancer
cell
Prior art date
Application number
DK12198310.0T
Other languages
English (en)
Inventor
Arezou Zargari
Nikolai Kouznetsov
Åsa Karlsson
Stein Oliver Von
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Application granted granted Critical
Publication of DK2573176T3 publication Critical patent/DK2573176T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (10)

1
1. Isoleret oligonukleotid, som består af en sekvens ifølge SEQ ID NO: 4.
2. Oligonukleotid ifølge krav 1 til anvendelse til behandling af cancer, hvor behandlingen er en immunologisk behandling og omfatter administration af et antistof til patienten, og hvor oligonukleotidet administreres inden administrationen af et antistof.
3. Oligonukleotid ifølge krav 1 til anvendelse til behandling af cancer ifølge krav 2, hvor oligonukleotidet administreres 30 minutter, 1 time, 2 timer, 3 timer, 6 timer eller 12 timer inden administrationen af antistoffet.
4. Oligonukleotid ifølge krav 1 til anvendelse til behandling af cancer ifølge 15 krav 2, hvor oligonukleotidet administreres topisk til en slimhinde eller subkutant i en dosis, som er effektiv til at inducere apoptose til behandling af cancer, og hvor dosen forefindes i intervallet fra ca. 0,01 til ca. 100 pg pr. kg kropsvægt.
5. Oligonukleotid ifølge krav 1 til anvendelse til behandling af cancer ifølge 20 krav 2, hvor oligonukleotidet administreres topisk til en slimhinde eller subkutant i en dosis, som er effektiv til at opregulere ekspressionen af mindst én af celleoverflademarkørerne CD20, CD23, CD25, CD40, CD54, CD69, CD80 og CD86, og hvor dosen forefindes i intervallet fra ca. 0,01 til ca. 100 pg pr. kg kropsvægt. 25
6. Oligonukleotid ifølge krav 1 til anvendelse til behandling af cancer ifølge krav 2, hvor oligonukleotidet administreres topisk til en slimhinde eller subkutant i en dosis, som er effektiv til at aktivere NK-celler, og hvor dosen forefindes i intervallet fra ca. 0,01 til ca. 100 pg pr. kg kropsvægt. 30
7. Oligonukleotid ifølge krav 1 til anvendelse til behandling af cancer ifølge krav 2, hvor behandlingen af cancer indebærer opregulering af ekspressionen 2 af mindst én af celleoverflademarkørerne CD20 og CD23 inden administrationen af et antistof til patienten.
8. Oligonukleotid ifølge krav 1 til anvendelse til behandling af cancer ifølge 5 krav 2, hvor behandlingen af cancer indebærer aktivering af NK-celler.
9. Oligonukleotid ifølge krav 1 til anvendelse til behandling af cancer ifølge krav 2, hvor behandlingen af cancer indebærer induktion af apoptose.
10. Isoleret oligonukleotidsekvens ifølge krav 1, hvor mindst ét nukleotid har en phosphatrygradsmodifi kation.
DK12198310.0T 2007-05-04 2008-04-30 Tumorvæksthæmmende forbindelser og fremgangsmåder til anvendelse deraf DK2573176T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92758407P 2007-05-04 2007-05-04
EP08779302A EP2160465B1 (en) 2007-05-04 2008-04-30 Tumour growth inhibitory compounds and methods of their use

Publications (1)

Publication Number Publication Date
DK2573176T3 true DK2573176T3 (da) 2016-08-01

Family

ID=39943756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12198310.0T DK2573176T3 (da) 2007-05-04 2008-04-30 Tumorvæksthæmmende forbindelser og fremgangsmåder til anvendelse deraf

Country Status (6)

Country Link
US (1) US8309529B2 (da)
EP (2) EP2160465B1 (da)
JP (2) JP5346923B2 (da)
DK (1) DK2573176T3 (da)
ES (1) ES2581480T3 (da)
WO (1) WO2008136748A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410068B2 (en) * 2007-10-05 2013-04-02 Index Pharmaceuticals Ab Compounds for the treatment or alleviation of edema, and methods for their use
US20110182880A1 (en) * 2008-06-18 2011-07-28 Oliver Von Stein Combination Therapies Against Cancer
EP2342341B1 (en) 2008-11-04 2014-03-05 Index Pharmaceuticals AB Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
AU2009311753B2 (en) * 2008-11-04 2015-01-15 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS
US9157919B2 (en) * 2010-12-21 2015-10-13 Index Pharmaceuticals Ab Method for identifying biologically active oligonucleotides capable of modulating the immune system
JPWO2018174140A1 (ja) * 2017-03-23 2020-04-09 ナパジェン ファーマ, インコーポレテッドNapaJen Pharma, Inc. 癌細胞の接着活性阻害剤
EP3967307A1 (en) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498147B2 (en) 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
EP1176966B1 (en) * 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
WO2001097843A2 (en) * 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
KR101107818B1 (ko) * 2003-10-30 2012-01-31 콜레이 파마시티컬 그룹, 인코포레이티드 향상된 면역자극 효능을 가진 ｃ-부류 올리고뉴클레오티드유사체
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8410068B2 (en) * 2007-10-05 2013-04-02 Index Pharmaceuticals Ab Compounds for the treatment or alleviation of edema, and methods for their use

Also Published As

Publication number Publication date
EP2160465B1 (en) 2013-01-02
JP2010525811A (ja) 2010-07-29
JP2013255508A (ja) 2013-12-26
JP5844779B2 (ja) 2016-01-20
WO2008136748A1 (en) 2008-11-13
EP2573176A1 (en) 2013-03-27
JP5346923B2 (ja) 2013-11-20
EP2160465A4 (en) 2011-04-13
ES2581480T3 (es) 2016-09-06
US8309529B2 (en) 2012-11-13
WO2008136748A8 (en) 2009-07-23
US20100196356A1 (en) 2010-08-05
EP2160465A1 (en) 2010-03-10
EP2573176B1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
JP6885867B2 (ja) 組合せ腫瘍免疫療法
DK2573176T3 (da) Tumorvæksthæmmende forbindelser og fremgangsmåder til anvendelse deraf
JP2022188225A (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
KR20200118904A (ko) 키메라 항원 수용체-변형된 nk-92 세포(chimeric antigen receptor-modified nk-92 cells)
JP5481068B2 (ja) ＣｐＧオリゴデオキシヌクレオチドによって誘発される免疫応答を変化させる方法
WO2015148879A1 (en) Cancer immunotherapy compositions and methods
WO2017083441A1 (en) Modified immune cells and uses thereof
Wang et al. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics
WO2010053433A1 (en) Increased expression of specific antigens
JP4837034B2 (ja) オリゴヌクレオチドまたはその機能的相同体、それらを含有する組成物およびｂ細胞腫瘍を治療するための方法
US20110182880A1 (en) Combination Therapies Against Cancer
JP2020515625A (ja) 細胞死およびインターフェロン発現の差次的誘導のための組成物および方法
Tarhini et al. Early development of the toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers
WO2024044628A2 (en) Oncolytic virus-infected immune cells and methods of use
WO2024211842A1 (en) Methods to treat cancer using anti-il-25 antibody
WO2012099871A1 (en) Modulation of lrch4 activity and therapeutic application thereof